Open Invitation Issued to Corporate and Government Organizations to Mitigate Pandemic

CAMPBELL, Calif.–(BUSINESS WIRE)–#coronavirus—Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, announced today that it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium. The single goal is to integrate data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50%. Saama’s unique platform will allow researchers to dynamically visualize, analyze, and interrogate data across all available programs.

“As a life sciences software company we are humbled to work with and provide technology to the brilliant professionals who tirelessly toil to solve this worldwide crisis. Working in clinical analytics, we truly understand the value derived from integrating research data and applying machine learning and predictive analytics technologies to enable better science,” said Suresh Katta, Founder and CEO of Saama Technologies. “We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatments – and hopefully a cure – for SARS-CoV-2.”

“We won’t find rapid solutions for the SARS-CoV-2 pandemic with our data remaining so fragmented,” said David Shulkin, M.D., the Ninth Secretary, US Department of Veterans Affairs. “In order to adequately address this pandemic, we must share data from clinical studies across the research, healthcare, and pharma communities. By having comprehensive datasets and deep data analytics we will have the opportunity to make great progress.”

Companies interested in joining the EndPandemic National Data Consortium to collaborate and accelerate solutions to the pandemic should contact Saama at endpandemic@saama.com or 888.970.3550.

Saama is the #1 AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at www.saama.com and follow Saama @SaamaTechInc.